At Odds About the Odds: Women's Choices to Accept Osteoporosis Medications Do Not Closely Agree with Physician-Set Treatment Thresholds
Overview
Affiliations
Background: Osteoporosis guidelines recommend pharmacologic therapy based on 10-year risk of major osteoporotic fracture (MOF) and hip fracture, which may fail to account for patient-specific experiences and values.
Objective: We aimed to determine whether patient decisions to initiate osteoporosis medication agree with guideline-recommended intervention thresholds.
Design And Participants: This prospective cohort study included women aged ≥ 45 with age-associated osteoporosis who attended a group osteoporosis self-management consultation at a tertiary osteoporosis center.
Intervention: A group osteoporosis self-management consultation, during which participants received osteoporosis education and then calculated their 10-year MOF and hip fracture risk using FRAX and their predicted absolute fracture risk with therapy (assuming 40% relative reduction). Participants then made autonomous decisions regarding treatment initiation.
Main Measures: We evaluated agreement between treatment decisions and physician-set intervention thresholds (10-year MOF risk ≥ 20%, hip fracture risk ≥ 3%).
Key Results: Among 85 women (median [IQR] age 62 [58-67]), 27% accepted treatment (median [IQR] MOF risk, 15.1% [9.9-22.0]; hip fracture risk, 3.3% [1.3-5.3]), 46% declined (MOF risk, 9.5% [6.5-11.6]; hip fracture risk, 1.8% [0.6-2.3]), and 27% remained undecided (MOF risk, 14.0% [9.8-20.2]; hip fracture risk, 4.4% [1.7-4.9]). There was wide overlap in fracture risk between treatment acceptors and non-acceptors. Odds of accepting treatment were higher in women with prior fragility fracture (50% accepted; OR, 5.3; 95% CI, 1.9-15.2; p = 0.0015) and with hip fracture risk ≥ 3% (32% accepted; OR, 3.6; 95% CI, 1.4-9.2; p = 0.012), but not MOF risk ≥ 20% (47% accepted; OR, 3.0; 95% CI, 1.0-8.5; p = 0.105).
Conclusions: Informed decisions to start osteoporosis treatment are highly personal and not easily predicted using fracture risk. Guideline-recommended intervention thresholds may not permit sufficient consideration of patient preferences.
Fasth L, Kelley C, Colon-Emeric C, Green A, Thorpe C, Gilliam M Drugs Aging. 2025; 42(2):155-164.
PMID: 39827439 PMC: 11848725. DOI: 10.1007/s40266-024-01179-w.
Decision threshold models in medical decision making: a scoping literature review.
Scarffe A, Coates A, Brand K, Michalowski W BMC Med Inform Decis Mak. 2024; 24(1):273.
PMID: 39334341 PMC: 11429414. DOI: 10.1186/s12911-024-02681-2.
Rubaek M, Broholm-Jorgensen M, Andersen S, Jakobsen P, Rothmann M, Langdahl B BMC Geriatr. 2024; 24(1):346.
PMID: 38627654 PMC: 11022455. DOI: 10.1186/s12877-024-04957-8.
Deprescribing bisphosphonates for older adults with dementia: perspectives of caregivers.
Niznik J, Kelley C, Fasth L, Colon-Emeric C, Thorpe C, Gilliam M Osteoporos Int. 2023; 35(4):589-598.
PMID: 37980284 PMC: 11145563. DOI: 10.1007/s00198-023-06967-5.
Billington E, Miyagishima R, Hasselaar C, Arain M Osteoporos Int. 2023; 34(12):2069-2076.
PMID: 37608123 DOI: 10.1007/s00198-023-06890-9.